# Globus Medical account plan

> Globus Medical makes spine, trauma and joint implants, spinal cord stimulators and surgical robots: FY2025 net sales $2,938.9 million, over 6,000 employees.

## At a glance

Globus Medical, Inc., founded in 2003 and headquartered in Audubon, Pennsylvania, is a musculoskeletal medical device company. It sells spine, orthopedic trauma, hip and knee implants, biologics, intraoperative neuromonitoring, spinal cord stimulation (through Nevro, acquired April 3, 2025) and the Excelsius imaging, navigation and robotics systems, mainly to hospitals, ambulatory surgery centers and surgeons in the U.S. and 64 countries outside it. FY2025 net sales were $2,938.9 million (up 16.7%), operating income $479.8 million and net income $537.9 million. It had over 6,000 employees at December 31, 2025. It is an NYSE controlled company: Executive Chairman David C. Paul and family hold about 66.1% of voting power.

## Business units

- **Musculoskeletal Solutions** ($2,797.9 million of FY2025 net sales, about 95% of the group): Spine fusion and motion-preservation implants, biologics, orthopedic trauma (PRECICE, ANTHEM), hip and knee arthroplasty, intraoperative neuromonitoring and Nevro's HFX spinal cord stimulation platform. Q3 2026 sales were $728.9 million versus $741.0 million, as spinal cord stimulation sales fell while U.S. spine, trauma and neuromonitoring grew.
- **Enabling Technologies** ($141.0 million of FY2025 net sales, about 5% of the group): The ExcelsiusGPS robot, Excelsius3D imaging, ExcelsiusHub navigation, ExcelsiusFlex knee robotics and the ExcelsiusXR headset, sold or placed through leases and rentals to hospitals. Q3 2026 sales rose to $34.9 million from $28.0 million, with U.S. unit deployment up 52%.

## Strategic priorities

- **Product launches in spine**: SCRIPT patient-specific implants and rods, the XLIF prone lateral solution and the EIQ pedicle fixation suite with AI planning are expected to be "meaningful contributors to revenue in 2027 and beyond"; well over 60 projects are in development.
- **Competitive sales rep recruiting**: Grow the exclusive U.S. sales force; Q2 2026 hires were double those of Q1, and recruiting remains central to the growth strategy.
- **Surgical intelligence ecosystem**: Combine implants, enabling technology, procedural solutions and AI-based surgeon intelligence; Higgs-Boson was acquired to build a "surgical intelligence layer".
- **Margin recovery**: Adjusted gross margin of 69% to 70% expected for 2026 with a return to the mid-70s targeted; adjusted EBITDA margin was 34.3% in Q3 2026.
- **Stabilise Nevro**: Rehire Nevro sales staff and recover trial volumes; HFX Elite, the first new IPG since the acquisition, is slated for the first half of 2027.
- **2027 growth ambition**: Not guidance: the CEO's goal is "growing mid to high single digits top line" with earnings outgrowing revenue, while R&D spending steps up.

## Latest results

Q3 2026 net sales were $763.7 million, down 0.7% from $769.0 million; the base business excluding Nevro was $690 million, up 3%, while Nevro fell 25.7% to $73.7 million. U.S. sales were $621.0 million (+0.5%) and international $142.7 million (-5.7%). Net income rose to $141.2 million and diluted EPS to $1.04, helped by manufacturing cost cuts and a lower litigation provision. For the nine months, net sales were $2,313.2 million (+9.5%). 2026 revenue guidance was cut to $3.09 billion from $3.18-$3.22 billion, while non-GAAP EPS guidance of $4.95-$5.05 was reiterated.

## Investments and deals

- **Nevro acquisition**: Acquired April 3, 2025 for $5.85 per share in cash; it contributed $293.6 million of revenue in 2025 and a $117.7 million bargain purchase gain.
- **Tuck-in acquisitions**: Higgs-Boson (digital and AI surgical intelligence) and the Synaptive assets (entry into cranial neurosurgery, about 2 million procedures a year) closed in Q3 2026.
- **Share buybacks**: 3.5 million shares repurchased for $279.0 million in the first nine months of 2026; on November 2, 2026 the board added $500.0 million, leaving about $611.0 million available.
- **Surgical sets and capacity**: Capital priorities put internal product development first, then surgical sets and manufacturing capacity, then buybacks, then M&A.

## Challenges and risks

- **Spine execution**: The CEO blamed "timing delays with new product introductions and lingering production issues" and lower contributions from competitive recruiting for U.S. Spine growth of 1.8% in Q3 2026.
- **Nevro decline**: Spinal cord stimulation sales fell $22.1 million in the U.S. in Q3 2026 on lower trial volumes; Nevro revenue fell 25.7%.
- **Capital model transition**: The shift to rental, lease and volume-based robot placements lowers upfront Enabling Technologies revenue; capital sales cycles are long and variable.
- **Pricing, reimbursement and competition**: Procedures move to outpatient settings with lower reimbursement, payors require prior authorisation, and Medtronic, DePuy Synthes, Stryker, Zimmer Biomet and Smith + Nephew compete.
- **Litigation**: A $43.1 million liability was recorded for the Pimenta case against NuVasive, and a 4WEB patent suit concerns Modulus products.

## What leadership says

> "I think there's things that we could have done better to achieve the growth that we thought we were going to get." — Keith Pfeil, President and CEO, Q3 2026 earnings call, November 5, 2026

> "since 2022, Globus has more than tripled our top line and earnings" — Keith Pfeil, President and CEO, Q2 2026 earnings call, August 6, 2026

> "Our strategy doesn't move from quarter to quarter" — Keith Pfeil, President and CEO, Q3 2026 earnings call, November 5, 2026


## Where a supplier can help

- **Manufacturing and supply reliability**: Tied to the spine execution challenge: suppliers and production partners that ease lingering production issues and support launches such as SCRIPT 3D-printed cages fit the launch plan.
- **Sales force recruiting and enablement**: Tied to the competitive recruiting priority: recruiting, onboarding and sales productivity tools support the exclusive U.S. sales force.
- **AI and surgical data**: Tied to the surgical intelligence ecosystem priority: data platforms, AI planning software and cloud infrastructure fit the Higgs-Boson and EIQ work.
- **Capital placement financing**: Tied to the capital model transition: leasing, financing and asset-tracking services could support rental and volume-based robot placements.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Globus Medical Form 10-K for fiscal year 2025 (year ended December 31, 2025)](https://www.sec.gov/Archives/edgar/data/1237831/000162828026011209/gmed-20251231.htm)

Annual report · 2026-02-24

- Globus Medical (Audubon, Pennsylvania; founded 2003) is a musculoskeletal medical device company selling spine, orthopedic trauma, hip and knee implants, biologics, intraoperative neuromonitoring (IONM), spinal cord stimulation (via Nevro) and the Excelsius imaging, navigation and robotics (INR) ecosystem, mainly to hospitals, ambulatory surgery centers and surgeons.
- FY2025 net sales were $2,938.9 million, up 16.7%, driven by the Nevro acquisition (Nevro sales of $254.2 million in the U.S. and $39.4 million internationally); U.S. sales were $2,367.6 million (+18.4%) and international $571.3 million (+10.0%, about 19.4% of total).
- Revenue is reported in two categories: Musculoskeletal Solutions ($2,797.9 million) and Enabling Technologies ($141.0 million, down from $154.0 million on lower U.S. unit placement); one reportable segment.
- Profitability jumped: operating income $479.8 million (vs $166.0 million), net income $537.9 million and diluted EPS $3.92 (vs $0.75), helped by the end of NuVasive inventory step-up amortization and a $117.7 million bargain purchase gain on Nevro.
- Strategy: rapid product development (9 launches in 2025, including ExcelsiusXR), a larger exclusive U.S. sales force, international expansion (presence in 64 countries outside the U.S.) and selective acquisitions (NuVasive in 2023, Nevro in April 2025 at $5.85 per share in cash).
- Over 6,000 employees; implants made in Pennsylvania and Ohio, Excelsius robots assembled in Methuen (MA), Nevro SCS devices made in Costa Rica.
- Governance: controlled company; Executive Chairman David C. Paul and family hold about 66.1% of voting power; Keith W. Pfeil replaced Daniel Scavilla as CEO in 2025.
- Capital return: 4.3 million shares repurchased for $300.5 million in 2025; the $450.0 million 2025 convertible notes were repaid; operating cash flow $753.4 million.
- Key risks: pricing pressure and reimbursement, competition from Medtronic, DePuy Synthes, Stryker, Zimmer Biomet and Smith + Nephew, long capital sales cycles for Enabling Technologies, acquisition integration, tariffs, and litigation (a $43.1 million liability recorded for the Pimenta case against NuVasive).

### [Globus Medical Form 10-Q for the third quarter of 2026 (quarter ended September 30, 2026)](https://www.sec.gov/Archives/edgar/data/1237831/000162828026071165/gmed-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 net sales were $763.7 million, down 0.7% from $769.0 million; U.S. $621.0 million (+0.5%), international $142.7 million (-5.7%).
- Nine-month 2026 net sales were $2,313.2 million (+9.5%); international was approximately 20.2% of total sales.
- Spinal cord stimulation (Nevro) product sales fell $22.1 million in the U.S. in Q3 on lower trial volumes; spine implants (+$8.1 million), trauma (+$5.5 million) and neuromonitoring (+$5.0 million) grew in the U.S.
- Enabling Technologies sales rose to $34.9 million in Q3 (from $28.0 million), with U.S. unit deployment up 52%; Musculoskeletal Solutions were $728.9 million (from $741.0 million).
- Q3 net income was $141.2 million and diluted EPS $1.04 (vs $0.88); cost of sales fell to 30.5% of sales on manufacturing cost-cutting; SG&A fell 8.0% on a $24.6 million lower litigation provision.
- Nine-month operating cash flow was $677.3 million (vs $504.9 million); 3.5 million shares were repurchased for $279.0 million year to date.
- On November 2, 2026 the Board added $500.0 million to the buyback program, leaving about $611.0 million available.
- Leadership: Keith W. Pfeil, President and CEO; Kyle R. Kline, CFO and Senior Vice President.

### [Globus Medical Q3 2026 earnings call transcript](https://www.earningswhispers.com/transcript/GMED/Q32026)

Executive talk · Keith Pfeil, President and Chief Executive Officer (with Kyle Kline, Chief Financial Officer) · 2026-11-05

- Q3 2026 revenue was $763.7 million (-0.7% as reported); base business (excluding Nevro) was $690 million, up 3%, while Nevro fell 25.7% to $73.7 million.
- CEO Keith Pfeil blamed execution rather than the market: delayed spine launches, "lingering production issues" and lower contributions from competitive rep recruiting; U.S. Spine grew 1.8%.
- 2026 revenue guidance was cut to $3.09 billion (from $3.18-$3.22 billion); non-GAAP EPS guidance of $4.95-$5.05 was reiterated; Q3 non-GAAP EPS was $1.23 and free cash flow a record $225 million.
- Launches for 2027: SCRIPT patient-specific implants and rods, the XLIF prone lateral solution with the two-blade retractor, the EIQ pedicle fixation suite with AI planning, and HFX Elite (Nevro's first new IPG under Globus) in the first half of 2027.
- Enabling Technologies sales grew 24.3% to $34.9 million; units deployed (sold, leased or rented) grew 45% as customers move to rental, lease and volume-based models; the FDA closed the July 2024 ExcelsiusGPS warning letter.
- Two tuck-in deals: Higgs-Boson (digital and AI surgical intelligence) and the Synaptive assets (entry into cranial neurosurgery, about 2 million procedures a year).
- Pfeil's 2027 ambition (not guidance): "growing mid to high single digits top line" with earnings outgrowing revenue; R&D spending to step up.
- Adjusted gross margin 69.5%, target 69-70% for 2026 and a return to the mid-70s; the board added $500 million to the buyback.

### [Globus Medical Q2 2026 earnings call transcript](https://allmind.ai/earnings/event/2943984)

Executive talk · Keith Pfeil, President and Chief Executive Officer (with Kyle Kline, Chief Financial Officer) · 2026-08-06

- Q2 2026 revenue was $789.6 million (+5.9% as reported); excluding Nevro, growth was 9%, with U.S. Spine +7.3% and international Spine +13.8%.
- Non-GAAP EPS was a record $1.34 (+55.8%); adjusted EBITDA margin 35.4% (28% a year earlier); adjusted gross margin 69.4%.
- Nevro sales fell 14.3% but its standalone adjusted EBITDA margin reached 22.4% after 2025 cost actions; about 75% of open sales roles were refilled.
- Enabling Technologies sales fell 25.8% to $26.1 million as Globus shifts to flexible capital acquisition models; units deployed grew; over 137,000 robotic procedures performed.
- Trauma grew 31% and neuromonitoring over 30%; launches: AUTOBAHN Hip Fastener, TENSOR Suture Button, Reline1; SCRIPT patient-specific spacers and rods cleared by the FDA, with well over 60 projects in development.
- Guidance: 2026 revenue $3.18-$3.22 billion reaffirmed; non-GAAP EPS raised to $4.95-$5.05 (from $4.70-$4.80); R&D 5% to 6% of sales with a second-half ramp.
- Buybacks: $136.1 million in Q2; since the NuVasive merger, $747 million spent buying back 11.9 million shares.
- Pfeil: Globus has "more than tripled our top line and earnings" since 2022 and is building a "surgical intelligence ecosystem".

## Questions about Globus Medical

### What does Globus Medical do?

Globus Medical makes spine, orthopedic trauma, hip and knee implants, biologics, neuromonitoring services, Nevro spinal cord stimulators and the Excelsius robotic and navigation systems used by surgeons.

### What is Globus Medical's revenue?

FY2025 net sales were $2,938.9 million, up 16.7%; 2026 revenue guidance is $3.09 billion.

### How many employees does Globus Medical have?

Over 6,000 employees worldwide at December 31, 2025.

### Who leads Globus Medical?

Keith W. Pfeil is President and CEO, Kyle R. Kline is CFO and David C. Paul is Executive Chairman.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
